Abstract

Cost-effective threshold (CET) is essential for health technology assessment and decision-making based on health economic evaluations. Recently, it has been argued that the commonly used once and three times of gross domestic product (GDP) per capita CETs of a quality-adjusted life year (QALY) are not necessarily empirically supported in all countries. Therefore, we aimed to estimate the CET of a QALY as times of GDP per capita in China, of which the reimbursement coverage decisions are increasingly engaging economic evaluations. Estimates on the value of statistical life (VSL) in China were identified from several studies in the literature and converted to times of GDP per capita, the weighted average of which was used for subsequent calculation. By pooling data on population mortality, health utility, and age distribution, we estimated the value of a statistical QALY (VSQ) from VSL using an established mathematical process, which represented the theoretical upper bound of CET. The corresponding point estimate and theoretical lower bound were obtained using their numerical relationships with the upper bound. Scenarios analyses were also conducted. The estimated CET, its upper bound, and its lower bound were 1.45, 2.90, and 1.16 times of GDP per capita in China, respectively. In different scenarios, the estimated CET varied but was greater than once GDP per capita in most cases. As such, the CET of a QALY in China is close to 1.5 times of GDP per capita, which should be benchmarked for future ICER-based coverage decisions.

Highlights

  • Used in drug reimbursement policymaking and designs of vaccination programs, cost-effectiveness analysis (CEA) is an important tool to inform healthcare decisions [1]

  • To elaborate the estimation of value of a statistical QALY (VSQ) based on value of statistical life (VSL), it is important to introduce the estimation of the value of a life year (VoLY) first

  • It was noteworthy that most studies we identified were conducted in relatively wealthy regions of China, such that the VSL estimates were unlikely to be representative nationwide

Read more

Summary

Introduction

Used in drug reimbursement policymaking and designs of vaccination programs, cost-effectiveness analysis (CEA) is an important tool to inform healthcare decisions [1]. Increasingly popular as an auxiliary tool for price negotiation, CEA does not have a formal role in public or private financing decisions except for immunization programs [2] in fragmented and decentralized healthcare systems such as the United States (US). Unlike the US, CEA is used to guide price-setting in markets like Japan and Germany [3, 4]. In China, CEA has received growing attention in the drug benefit design process of the National Healthcare Security Administration (NHSA) in recent years, it is not yet a compulsory part of the reimbursement

Objectives
Methods
Findings
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.